Series Author Debuts First Single-Title Novel

Iowa, LA (PRWEB) July 10, 2007

Pamela S Thibodeaux, Author of "Inspirational with an Edge!" romantic fiction and The Wild Rose Press announce the release of Thibodeaux's first single-title novel, The Inheritance. Initially released March 27th as an E-book, print copies of The Inheritance hit the shelves on June 22nd.

The Inheritance (ISBN 1-60154-055-8) is about the chance we all long for.the chance to start over.

Widowed at age thirty-nine and suffering from empty nest syndrome, Rebecca Sinclair is overshadowed by grief and loneliness. Her husband has been deceased for a year, her oldest child has moved to New York in pursuit of an acting career and her youngest child is attending college in France. Having spent over half of her life as a wife and mother, she has no idea what God has in store for her now. Will an unexpected inheritance in the wine country of New York bring meaning and purpose to her life and give her the courage to love again?

US Postal worker Raymond Jacobey has been in love with the little widow since he first set eyes on her. A wanderer searching for the ever-illusive soul mate, Ray has never stayed in one place too long. Raised by self-centered, high-power executives, he's longed for the idyllic life of residing in a cozy house in a small town with the love of his life. Will he gain the heart of the lovely widow or will he lose her to the wine country of New York?

While Thibodeaux's debut at publication began with her "Tempered" series, this is her first single-title novel. Initially published as an E-book in March, The Inheritance has climbed to the #1 spot on The Wild Rose Press' "Current Best Seller" list for their White Rose (Inspirational) Line.

The Inheritance as well as Thibodeaux's "Tempered" books, Tempered Hearts, Tempered Dreams and Tempered Fire are available at your favorite bookstore, the publisher's website, and online sources Amazon.com; BAMM.com (Books-A-Million); Waldenbooks.com and (Barnes & Noble) barnesandnoble.com.

For more information feel free to contact Rhonda Penders or RJ Morris of The Wild Rose Press @ http://www.thewildrosepress.com or Mrs. Thibodeaux @ http://www.pamelathibodeaux.com

###

University Of Albany Research Study Demonstrates Novel Mechanism Of Action For New Hair Growth Formulation

Rensselaer, NY (PRWEB) July 2, 2010

Because chronic inflammation of the hair follicle is considered a contributing factor in the onset and progression of common pattern hair loss, study investigators Sridar Chittur, Brian Parr & Geno Marcovici sought to measure the test material's activity in blocking key markers of pathologic inflammation by using a well-validated molecular assay representative of hair follicle keratinocytes. Specifically, the research team found that the test compound suppressed gene expression of several inflammatory chemokines potentially linked to hair loss.

Hair loss affects over forty million American men and twenty million American women. The hair loss treatment industry represents a multi-billion dollar revenue stream annually.

In addition to anti-inflammatory agents, TS050508A was formulated with a subset of botanically derived, highly potent DHT inhibitors. DHT is a well-known trigger of pattern hair loss. Thus, by combining targeted anti-inflammatory agents with potent DHT inhibitors the test composition has been designed to offer enhanced clinical efficacy over conventional monotherapy.

Lead scientist for the study Sridar Chittur, Ph.D. has been at the forefront of molecular research authoring published works ranging from degenerative mitral valve disease (DMVD), to transcriptional changes associated with oxidative stress in the mitochondria. Co-author Brian Parr, Ph.D. brings a wealth of basic science expertise to the project with a number of peer-reviewed papers describing novel gene transcription and protein expression profiles in the Wnt and Frizzled pathways.

Study co-author Geno Marcovici, Ph.D. has been active in the hair loss field for more than a decade. His research efforts include the first published clinical trial successfully testing naturally derived 5 alpha reductase inhibitors in the setting of pattern hair loss. Explaining the importance of validating ART's proprietary formulations Marcovici notes that "[a]side from HairGenesis